|
|
| | (S)-ROSCOVITINE Basic information |
| Product Name: | (S)-ROSCOVITINE | | Synonyms: | (2S)-2-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol;Roscovitine, (S)-Isomer - CAS 186692-45-5 - Calbiochem;1-Butanol, 2-[[9-(1-methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-, (2S)- | | CAS: | 186692-45-5 | | MF: | C19H26N6O | | MW: | 354.45 | | EINECS: | | | Product Categories: | | | Mol File: | 186692-45-5.mol |  |
| | (S)-ROSCOVITINE Chemical Properties |
| Melting point | 103-106℃ | | density | 1.25 | | storage temp. | -20C | | form | White solid | | color | White to off-white |
| | (S)-ROSCOVITINE Usage And Synthesis |
| Uses | (S)-Roscovitine ((S)-Seliciclib; (S)-CYC202) is a potent and cross the blood-brain barrier CDKs inhibitor. (S)-Roscovitine shows neuroprotective efficacy. (S)-Roscovitine has the potential for the research of stroke[1][2]. | | in vivo | (S)-Roscovitine (25 mg/kg; i.p.; 15 min before and 1 hr after pMCAo) shows neuroprotective efficacy in an adult mouse model of permanent MCAo (middle cerebral artery occlusion) [2]. | Animal Model: | 20-25 g, P60 male C57 b/6 mice[2] | | Dosage: | 25 mg/kg | | Administration: | I.p.; at 15 min before and 1 hr after pMCAo | | Result: | Decreased of the total infarct volume. |
| | IC 50 | CDK1: ≤1 μM (IC50); CDK2: ≤1 μM (IC50); CDK5: ≤1 μM (IC50); CDK7: ≤1 μM (IC50); CDK9: ≤1 μM (IC50) | | storage | +4°C | | References | [1] Le Roy L, et al. Cellular and Molecular Mechanisms of R/S-Roscovitine and CDKs Related Inhibition under Both Focal and Global Cerebral Ischemia: A Focus on Neurovascular Unit and Immune Cells. Cells. 2021 Jan 8;10(1):104. DOI:10.3390/cells10010104
[2] Menn B, et al. Delayed treatment with systemic (S)-roscovitine provides neuroprotection and inhibits in vivo CDK5 activity increase in animal stroke models. PLoS One. 2010 Aug 12;5(8):e12117. DOI:10.1371/journal.pone.0012117 |
| | (S)-ROSCOVITINE Preparation Products And Raw materials |
|